Multiple Myeloma Research Consortium (MMRC) Activates Clinical Trials 30-40 Percent Faster Than Industry Standard
The Multiple Myeloma Research Consortium (MMRC), an innovative research model comprised of a network of 15 academic Member Institutions across North America and leadership in Norwalk, Connecticut, announced preliminary data from an analysis showing that clinical trials opened through its clinical trials network were activated 30 to 40 percent faster than comparable clinical trials in oncology.
More: continued here
Filed under: Cancer on June 22nd, 2009
You must be logged in to post a comment.